The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute. This is a special funding opportunity separate from ADDF’s Therapeutic Funding Programs.

The award typically entails up to $600,000 over 2 years with dedicated support for milestone-driven projects from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.

Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, slow, or reverse Alzheimer’s disease or related dementias (vascular dementia, frontotemporal dementia, Lewy Body dementia, LATE etc).

Letter of Intent: June 3, 2024, 5:00 PM EDT
Full Proposal: August 26, 2024, 5:00 PM EDT